PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Bought by Northern Trust Corp

Northern Trust Corp lifted its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 15.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 446,468 shares of the company's stock after buying an additional 60,098 shares during the period. Northern Trust Corp owned about 0.86% of PROCEPT BioRobotics worth $35,950,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of PRCT. Wilmington Savings Fund Society FSB bought a new position in shares of PROCEPT BioRobotics during the third quarter worth approximately $64,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in PROCEPT BioRobotics during the 4th quarter worth $453,000. Hennion & Walsh Asset Management Inc. increased its position in PROCEPT BioRobotics by 62.5% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 9,624 shares of the company's stock valued at $775,000 after acquiring an additional 3,702 shares during the period. KRS Capital Management LLC lifted its holdings in PROCEPT BioRobotics by 0.5% during the 4th quarter. KRS Capital Management LLC now owns 46,455 shares of the company's stock worth $3,741,000 after buying an additional 225 shares during the period. Finally, Oak Ridge Investments LLC lifted its position in shares of PROCEPT BioRobotics by 24.0% in the 4th quarter. Oak Ridge Investments LLC now owns 30,059 shares of the company's stock worth $2,420,000 after purchasing an additional 5,817 shares during the period. 89.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PRCT has been the topic of a number of research reports. Morgan Stanley dropped their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Bank of America dropped their target price on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Friday, April 25th. Finally, Truist Financial dropped their price objective on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $90.00.

PROCEPT BioRobotics Price Performance

PRCT stock traded down $1.40 during trading on Tuesday, reaching $53.04. The company's stock had a trading volume of 1,292,402 shares, compared to its average volume of 808,595. The company's fifty day moving average is $55.33 and its 200-day moving average is $72.66. The company has a market capitalization of $2.93 billion, a P/E ratio of -27.20 and a beta of 1.10. PROCEPT BioRobotics Co. has a 1 year low of $47.04 and a 1 year high of $103.81. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.04. The firm had revenue of $69.16 million during the quarter, compared to analyst estimates of $65.39 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business's revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.51) EPS. On average, research analysts expect that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Reza Zadno sold 5,475 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the sale, the chief executive officer now directly owns 173,070 shares in the company, valued at approximately $9,875,374.20. The trade was a 3.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin Waters sold 733 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the sale, the chief financial officer now directly owns 107,991 shares in the company, valued at $6,161,966.46. This trade represents a 0.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,455 shares of company stock worth $368,322 in the last 90 days. Insiders own 6.60% of the company's stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).